Climb Bio develops antibody medicines for immune system diseases, including rare kidney and blood disorders. It last closed at $9.19 on Nov 20, down 0.97% on the day. The next earnings report for CLYM is expected around Thu, Mar 4, 2027. For the quarter ended Sep 2026, CLYM reported EPS of -$0.18. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months CLYM insiders bought $780K of stock on the open market and sold $2.7M, according to SEC Form 4 filings.
AI Auto Pilots
Is CLYM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CLYM.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on CLYMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
CLYM · as of the Nov 20 close · updated each morning
Turning down
The stock is 9% below its 20 day and 20% below its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 41). The nearest support is the Pivot at $9.16, and the nearest resistance the Pivot R1 at $9.43.
Short trendBearish
Long trendNeutral
MomentumWeak
StretchNormal
VolatilityNormal, 9.6%/day
Key levels
$18.3352 week high+99.5%
$12.60100 day average+37.1%
$11.0150 day average+19.8%
$10.79200 day average+17.4%
$10.55Swing high (Oct 29)+14.8%
$10.0420 day average+9.2%
$9.43Pivot R1+2.6%
$9.19Last close
$9.16Pivot−0.3%
$8.93Pivot S1−2.8%
$8.70Swing low (Oct 26)−5.3%
$1.6452 week low−82.2%
Indicators
RSI (14)
40.54
Middle of its range
Neutral
MACD
-0.37
Below its signal line
Bearish
Stochastic
19.5
Near the bottom of its range
Oversold
ADX (14)
26.1
Trending down
Williams %R
-82.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-93.2
Oversold below −100, overbought above 100
Neutral
Rate of change
−10.7%
Change over 10 sessions
Bearish
ATR (14)
$0.89
Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 21.0%/day
Key levels
$18.3352 week high+99.5%
$12.60100 day average+37.1%
$11.0150 day average+19.8%
$10.79200 day average+17.4%
$10.55Swing high (Oct 29)+14.8%
$10.0420 day average+9.2%
$9.43Pivot R1+2.6%
$9.19Last close
$9.16Pivot−0.3%
$8.93Pivot S1−2.8%
$8.70Swing low (Oct 26)−5.3%
$1.6452 week low−82.2%
Indicators
RSI (14)
40.78
Middle of its range
Neutral
MACD
-0.12
Below its signal line
Bearish
Stochastic
14.8
Near the bottom of its range
Oversold
ADX (14)
26.8
Trending down
Williams %R
-92.8
Oversold below −80, overbought above −20
Oversold
CCI (20)
-110.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−35.5%
Change over 10 sessions
Bearish
ATR (14)
$1.93
Typical daily range, 21.0% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Above
What happened before, for CLYM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CLYM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow CLYM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for CLYMHow many large options trades hit CLYM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in CLYM in the last 90 days.
From SEC Form 4 filings by CLYM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLYM is in one of them and how their past CLYM trades turned out.
Climb Bio is a biotechnology company based in Wellesley Hills, Massachusetts. It is developing antibody medicines for diseases in which the immune system attacks the body. Its lead candidate, budoprutug, is designed to deplete a type of B cell and is being tested in patients with membranous nephropathy, a rare kidney disease, as well as immune thrombocytopenia and lupus. A second candidate, CLYM116, targets a protein linked to IgA nephropathy, a kidney condition. Its candidates are still in clinical trials and are not yet sold.